| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Zolimidine targets the gastrointestinal mucosa, where it stimulates mucus secretion by intestinal mucosal cells and enhances the resistance of the intestinal wall to ulcer formation. The compound's gastroprotective effects are mediated through this mechanism. In addition to its anti-ulcer activity, Zolimidine is being investigated as an inhibitor targeting specific molecular pathways involved in cancer progression and immune modulation.
|
|---|---|
| ln Vitro |
In vitro, Zolimidine has been studied for its effects on intestinal mucosal cells. The compound stimulates mucus secretion, which contributes to its gastroprotective effects. Its activity has also been evaluated in cancer and immunology research, where it inhibits specific molecular pathways. However, specific in vitro activity data are limited. The compound's effects are concentration-dependent.
|
| ln Vivo |
In rats given indomethacin (5 mg/kg/day for 8 days, rectal) as a cause of intestinal ulceration, zolimidine (200 mg/kg; oral) lowers the occurrence of this condition [2]. In guinea pigs, carrageenan (added to drinking water; 5% for 40 days) causes intestinal ulcers; zolimidine (added to the food; 1% lowers the occurrence of these ulcers) [2].
In vivo, Zolimidine is an orally active anti-ulcer agent. In animal models of duodenal ulcers, Zolimidine demonstrates gastroprotective effects by stimulating mucus secretion and enhancing the resistance of the intestinal wall to ulcer formation. The compound has been studied in preclinical models for its anti-ulcer activity. Its potential in oncology and immunology is also being explored. |
| Enzyme Assay |
Non-cell-based assays for Zolimidine involve characterization of its chemical properties. The compound's structure is confirmed by NMR and MS. Its purity is determined by HPLC. Receptor binding or enzyme inhibition assays may be used to study its interactions with specific molecular targets. The compound's chemical properties including molecular formula (C₁₄H₁₂N₂O₂S) and molecular weight (272.32) are characterized.
|
| Cell Assay |
Cellular assays for Zolimidine are performed using various cell lines including intestinal epithelial cells, cancer cells, and immune cells. Cells are treated with Zolimidine at various concentrations, and cellular responses are measured. Cell viability is measured by MTT assays. Mucus secretion is measured in intestinal epithelial cells. Anti-cancer activity is assessed by measuring cell proliferation and apoptosis. Immunomodulatory effects are evaluated by measuring cytokine production.
|
| Animal Protocol |
In vivo experiments with Zolimidine are conducted in animal models of duodenal ulcers. Animals are treated with Zolimidine via oral administration, and ulcer formation is induced by various methods. Gastroprotective effects are assessed by measuring ulcer index, mucus secretion, and histological analysis of gastric tissues. The compound's anti-cancer and immunomodulatory effects may also be evaluated in appropriate models.
|
| ADME/Pharmacokinetics |
Zolimidine is orally active and exhibits favorable pharmacokinetic properties as a small molecule drug. Following oral administration, the compound is absorbed from the gastrointestinal tract and distributed to target tissues. Its half-life, bioavailability, and metabolism have been characterized in preclinical studies. The compound's absorption, distribution, metabolism, and excretion are well-defined for an orally active agent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Zolimidine has been evaluated in preclinical studies. As an anti-ulcer agent, the compound is generally well-tolerated at therapeutic doses. Potential adverse effects may include gastrointestinal disturbances, which are common with this class of agents. Comprehensive toxicological studies including genotoxicity, organ toxicity, and maximum tolerated dose have been conducted to support its development.
|
| References | |
| Additional Infomation |
Zolimidine belongs to the imidazole class of compounds.
Zolimidine (CAS# 1222-57-7) is an imidazopyridine derivative with the molecular formula C₁₄H₁₂N₂O₂S and a molecular weight of 272.32. It is also known as 2-[4-(Methylsulfonyl)phenyl]imidazo[1,2-a]pyridine. Zolimidine is an orally active anti-ulcer agent that stimulates mucus secretion and enhances intestinal wall resistance to ulcers. It is also being researched for potential applications in oncology and immunology. As of current knowledge, Zolimidine may not be widely approved. |
| Molecular Formula |
C14H12N2O2S
|
|---|---|
| Molecular Weight |
272.32
|
| Exact Mass |
272.062
|
| CAS # |
1222-57-7
|
| PubChem CID |
14652
|
| Appearance |
Light yellow to brown solid powder
|
| Density |
1.31 g/cm3
|
| Index of Refraction |
1.653
|
| LogP |
3.485
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
410
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CS(=O)(=O)C1=CC=C(C=C1)C2=CN3C=CC=CC3=N2
|
| InChi Key |
VSLIUWLPFRVCDL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N2O2S/c1-19(17,18)12-7-5-11(6-8-12)13-10-16-9-3-2-4-14(16)15-13/h2-10H,1H3
|
| Chemical Name |
2-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (183.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6722 mL | 18.3608 mL | 36.7215 mL | |
| 5 mM | 0.7344 mL | 3.6722 mL | 7.3443 mL | |
| 10 mM | 0.3672 mL | 1.8361 mL | 3.6722 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
